Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.

IF 5 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2025-08-27 DOI:10.1007/s11912-025-01686-y

Eric H Bent, Michael J Morris

{"title":"Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions.","authors":"Eric H Bent, Michael J Morris","doi":"10.1007/s11912-025-01686-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: There has been a rapid increase in the use and investigation of radioligand therapies for prostate cancer. This review summarizes and synthesizes the current prostate cancer radioligand landscape. It highlights the challenges facing optimal radioligand use and outlines approaches to improve the efficacy of this therapeutic class.Recent findings: The prostate specific membrane antigen (PSMA)-directed radioligand 177Lu-PSMA-617 improves survival in patients with metastatic castrate resistant prostate cancer (mCRPC) after chemotherapy and is now a standard of care treatment option for these patients. Published and ongoing trials promise to expand the use of radioligand therapies in prostate cancer. These trials highlight the potential of novel radioligand targets, alternate radioisotopes, and combination therapy approaches to improve radioligand efficacy. Emerging radioligands, novel combination therapies, optimized patient selection, and dose-personalization promise to improve outcomes and expand the use of radioligand therapies in prostate cancer.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-025-01686-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: There has been a rapid increase in the use and investigation of radioligand therapies for prostate cancer. This review summarizes and synthesizes the current prostate cancer radioligand landscape. It highlights the challenges facing optimal radioligand use and outlines approaches to improve the efficacy of this therapeutic class.

Recent findings: The prostate specific membrane antigen (PSMA)-directed radioligand ¹⁷⁷Lu-PSMA-617 improves survival in patients with metastatic castrate resistant prostate cancer (mCRPC) after chemotherapy and is now a standard of care treatment option for these patients. Published and ongoing trials promise to expand the use of radioligand therapies in prostate cancer. These trials highlight the potential of novel radioligand targets, alternate radioisotopes, and combination therapy approaches to improve radioligand efficacy. Emerging radioligands, novel combination therapies, optimized patient selection, and dose-personalization promise to improve outcomes and expand the use of radioligand therapies in prostate cancer.

查看原文本刊更多论文

前列腺癌放射治疗：PSMA及以后，现状和未来方向。

综述目的：前列腺癌放射治疗的使用和研究迅速增加。本文对前列腺癌放射配体的现状进行了综述和综合。它强调了最佳放射配体使用所面临的挑战，并概述了提高这类治疗效果的方法。前列腺特异性膜抗原（PSMA）定向放射配体177Lu-PSMA-617可提高转移性去势抵抗性前列腺癌（mCRPC）患者化疗后的生存率，目前已成为这些患者的标准护理治疗选择。已发表和正在进行的试验有望扩大放射配体治疗在前列腺癌中的应用。这些试验强调了新的放射性配体靶点、替代放射性同位素和联合治疗方法的潜力，以提高放射性配体的疗效。新出现的放射配体、新的联合疗法、优化的患者选择和剂量个性化有望改善预后并扩大放射配体治疗在前列腺癌中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.